Trevi to present phase 2a trial data on chronic cough treatment at ERS

Investing.comThursday, September 18, 2025 at 11:38:26 AM
Trevi to present phase 2a trial data on chronic cough treatment at ERS
Trevi Therapeutics is set to present promising data from its phase 2a trial on a new treatment for chronic cough at the upcoming European Respiratory Society (ERS) conference. This is significant as chronic cough affects millions and finding effective treatments can greatly improve quality of life for patients. The presentation could also attract attention from investors and healthcare professionals, potentially leading to further advancements in respiratory therapies.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment stock outlook
PositiveFinancial Markets
Cytokinetics is making waves in the heart failure treatment landscape with its drug aficamten, which shows promising potential in reshaping hypertrophic cardiomyopathy (HCM) management. This development is significant as it could lead to improved patient outcomes and a positive shift in the company's stock outlook, reflecting investor confidence in innovative therapies. As the medical community looks for effective solutions for HCM, aficamten's success could mark a pivotal moment in treatment options.
EC approves Biogen's ZURZUVAE as first oral treatment for postpartum depression
PositiveFinancial Markets
The European Commission has approved Biogen's ZURZUVAE, marking a significant milestone as the first oral treatment for postpartum depression. This approval is crucial as it provides a new option for mothers experiencing this condition, which can severely impact their well-being and that of their families. With ZURZUVAE, patients may find relief in a more convenient form, potentially improving adherence to treatment and overall outcomes.
Povorcitinib shows promising results for hidradenitis suppurativa
PositiveFinancial Markets
Povorcitinib has shown promising results in clinical trials for treating hidradenitis suppurativa, a chronic skin condition that affects many patients. This breakthrough could offer new hope for those suffering from this painful disease, as effective treatments have been limited. The positive outcomes from these trials highlight the potential for povorcitinib to improve the quality of life for patients, making it a significant development in dermatological care.
Brainsway stock surges after FDA clears accelerated depression treatment
PositiveFinancial Markets
Brainsway's stock price has surged following the FDA's approval of its accelerated treatment for depression. This breakthrough could provide new hope for patients struggling with this condition.
Editor’s Note: The FDA's clearance of Brainsway's treatment is significant as it may offer faster relief for those suffering from depression. This approval not only boosts the company's stock but also highlights advancements in mental health therapies.
Latest from Financial Markets
Tiny IPOs Flourish Along With Indian Stock Market
PositiveFinancial Markets
The Indian stock market is experiencing a surge in tiny IPOs, reflecting a growing confidence among investors. This trend is significant as it indicates a vibrant economic environment and offers new opportunities for small businesses to access capital. As these IPOs flourish, they not only contribute to market diversity but also empower entrepreneurs, making it an exciting time for the Indian financial landscape.
S&P 500, Nasdaq, Dow and Russell 2000 Hit Record
PositiveFinancial Markets
Wall Street is celebrating as the S&P 500, Nasdaq, Dow, and Russell 2000 have all hit record highs, fueled by optimism over potential Federal Reserve rate cuts. This surge reflects traders' confidence in Corporate America's resilience and growth prospects. In a recent discussion on Bloomberg Businessweek Radio, Aaron Kennon, CEO of Clear Harbor Asset Management, shared insights on what this means for investors and the sustainability of this upward trend in equities. It's an exciting time for the market, and many are eager to see how long this momentum can last.
Fitch says Nepal’s political unrest risks economic outlook, credit metrics
NegativeFinancial Markets
Fitch Ratings has expressed concerns over Nepal's political unrest, warning that it poses significant risks to the country's economic outlook and credit metrics. This situation is crucial as it could affect investor confidence and economic stability, making it essential for stakeholders to monitor developments closely.
Korea Eases Equity Rules for Banks to Spur High-Tech Investment
PositiveFinancial Markets
South Korea has introduced new measures to encourage banks to shift their funding from property lending to vital sectors like semiconductors and artificial intelligence. This move is significant as it aims to boost investment in high-tech industries, which are crucial for the country's economic growth and competitiveness in the global market.
Asian shares to end big central bank week with gains, Nikkei hits record
PositiveFinancial Markets
Asian shares are set to close a significant week for central banks on a high note, with the Nikkei index reaching a record level. This surge reflects investor confidence and positive economic indicators, suggesting a robust recovery in the region. Such gains are crucial as they can influence global markets and signal a strengthening economy, making it an important development for investors and analysts alike.
Exclusive-South Korea’s LG Energy was using US visa workarounds before Trump, documents show
NegativeFinancial Markets
Recent documents reveal that LG Energy, a major South Korean company, was utilizing workarounds for US visa regulations even before the Trump administration. This raises concerns about compliance with immigration laws and the ethical implications of such practices. The revelation could impact LG Energy's reputation and its operations in the US, highlighting the ongoing complexities of international business and immigration policies.